Madrigal Pharmaceuticals Inc. (MDGL) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear

Madrigal Pharmaceuticals ...

NASDAQ: MDGL · Real-Time Price · USD
443.01
-6.63 (-1.47%)
At close: Oct 03, 2025, 3:59 PM
450.00
1.58%
After-hours: Oct 03, 2025, 07:29 PM EDT

Madrigal Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
515.55M 317.38M 180.13M 76.81M 14.64M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
20.59M 12.05M 7.33M 3.66M 1.35M 571K 527K 514K 500K 484K 467K 444K 420K 399K 405K 415K 433K 459K
Gross Profit
494.95M 305.33M 172.8M 73.15M 13.29M -571K -527K -514K -500K -484K -467K -444K -420K -399K -405K -415K -433K -459K
Operating Income
-309.81M -425.15M -497.88M -548.05M -530.28M -454.2M -380.5M -348.62M -330.5M -314.32M -293.57M -272.87M -255.62M -247.09M -242.48M -237.44M -233.06M -221.65M
Interest Income
41.7M 47.69M 46.65M 44.53M 34.81M 24.14M 19.58M 11.7M 9.12M 5.89M 2.19M 1.16M 504K 272K 363K 743K 1.51M 2.62M
Pretax Income
-281.9M -391.59M -465.89M -518.67M -510.45M -444.27M -373.63M -347.34M -329.8M -314.73M -295.35M -273.99M -255.9M -246.82M -241.85M -236.42M -231.28M -218.66M
Net Income
-281.9M -391.59M -465.89M -518.67M -510.45M -444.27M -373.63M -347.34M -329.8M -314.73M -295.35M -273.99M -255.9M -246.82M -241.85M -236.42M -231.28M -218.66M
Selling & General & Admin
613.54M 522.13M 435.06M 340.37M 260.37M 172.76M 108.15M 76.17M 60.73M 54.65M 48.13M 45.28M 41.43M 39.77M 37.32M 31.73M 28.94M 24.47M
Research & Development
192.27M 209.39M 236.28M 281.13M 283.34M 281.12M 272.21M 272.45M 269.77M 259.67M 245.44M 227.59M 214.19M 207.32M 205.16M 205.7M 204.12M 197.18M
Other Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
804.77M 730.48M 670.68M 621.2M 543.57M 453.63M 379.97M 348.11M 330M 313.84M 293.1M 272.43M 255.2M 246.69M 242.08M 237.02M 232.63M 221.19M
Interest Expense
13.74M 14.13M 14.67M 15.14M 14.97M 14.21M 12.71M 10.42M 8.42M 6.3M 3.96M 2.28M 780K n/a n/a n/a n/a n/a
Selling & Marketing Expenses
-152.61M -152.61M -152.61M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
825.36M 742.53M 678.01M 624.87M 544.92M 454.2M 380.5M 348.62M 330.5M 314.32M 293.57M 272.87M 255.62M 247.09M 242.48M 237.44M 233.06M 221.65M
Income Tax Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Shares Outstanding (Basic)
22.21M 22.09M 21.27M 21.75M 21.4M 20M 19.76M 18.48M 18.31M 18.19M 17.24M 17.1M 17.1M 17.1M 17.07M 16.64M 16.57M 15.84M
Shares Outstanding (Diluted)
22.21M 22.09M 21.27M 21.75M 21.4M 20M 19.76M 18.48M 18.31M 18.19M 17.24M 17.1M 17.1M 17.1M 17.07M 16.64M 16.57M 15.84M
EPS (Basic)
-12.64 -17.84 -21.9 -25.08 -25.5 -23.09 -19.99 -19.39 -18.89 -18.38 -17.47 -16.17 -15.12 -14.66 -14.61 -14.65 -14.61 -14.07
EPS (Diluted)
-12.64 -17.84 -21.9 -25.08 -25.5 -23.09 -19.99 -19.39 -18.89 -18.38 -17.47 -16.17 -15.12 -14.66 -14.61 -14.65 -14.61 -14.07
EBITDA
-266.74M -376.15M -450.13M -502.65M -494.76M -429.49M -360.39M -336.4M -320.88M -307.94M -290.92M -271.27M -254.7M -246.42M -241.44M -236M -230.85M -218.2M
EBIT
-268.16M -377.46M -451.22M -503.53M -495.48M -430.06M -360.92M -336.92M -321.38M -308.43M -291.39M -271.71M -255.12M -246.82M -241.85M -236.42M -231.28M -218.66M
Depreciation & Amortization
1.42M 1.31M 1.1M 875K 712K 571K 527K 514K 500K 484K 467K 444K 420K 399K 405K 415K 433K 459K